RT Journal Article
SR Electronic
T1 Zero-COVID policy or Living-with-COVID policy? Analysis Based on Percent Excess Mortality
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.31.22279422
DO 10.1101/2022.08.31.22279422
A1 Cao, Xiaohan
A1 Li, Yan
A1 Zi, Yunlong
A1 Zhu, Yuyan
YR 2022
UL http://medrxiv.org/content/early/2022/09/01/2022.08.31.22279422.abstract
AB Background Since the outbreak of the SARS-CoV-2 variant B.1.1.529 (Omicron) in late 2021, many countries adopted the living-with-COVID (LWC) policy instead of the zero-COVID (ZC) policy to restore pre-COVID-19 normalcy. However, given that the Omicron variant is much more contagious, whether the mortality burden under the LWC policy is tolerable to the society remains under debate.Methods In this study, four countries (Singapore, South Korea, Australia, and New Zealand) that have shifted to the LWC policy and one region (Hong Kong) with a significant Omicron outbreak were selected as research objects. Percent excess mortality (PEM), which is the percentage of excess mortality over expected mortality, was selected to assess the effectiveness of different anti-pandemic policies in controlling the mortality burden within the same country/region during the pandemic. In addition, confirmed COVID cases, COVID-associated deaths, percent COVID-excess mortality, expected and observed mortality over time were collected or calculated for further comparisons.Results In the examined four countries, PEM fluctuated around 0 and was lower than 10% most of the time under the ZC policy. After shifting to the LWC policy, PEM usually exceeded 10%, and countries with high population density experienced a peak PEM of 20-70%. New Zealand was the only country in our analysis that achieved approximately 10% average PEM during the Omicron outbreak under the LWC policy. Hong Kong, under a specialized ZC policy, attained a significant high PEM during the Omicron outbreak.Conclusion Our analysis demonstrated that PEM was significantly higher during the LWC policy period than that during the ZC policy period. Thus, the precondition of the policy transition needs to be cautiously examined, and the current LWC policy should be revised to achieve a lower PEM.HighlightsPercent excess mortality (PEM) threshold of 10% might be set as a criterion to assess the effectiveness of anti-pandemic policies in controlling the mortality burdenUnder the current version of living-with-COVID (LWC) policy, countries with a high population density might face a peak PEM of 20-70% and an average PEM of more than 10% during the pandemic outbreaks.Omicron’s contribution to PEM was not less than that of Delta within the same country.Ultrahigh vaccination coverage significantly helped New Zealand to control average PEM well during the Omicron outbreak under the LWC policy.PEM can serve as a useful indicator to evaluate the effectiveness of the anti-pandemic policies in controlling the mortality burden.Table abstract Summary of percent excess mortality stratified by the zero-COVID policy and the living-with-COVID policy, including peak and average percent excess mortality for SARS-CoV-2 Delta and Omicron variants and their corresponding durations for four countries and one region.View this table:Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by PolyU Internal Funding (#P0030234) to Y.Z.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:https://tablebuilder.singstat.gov.sg/table/TS/M810121 https://news.google.com/covid19/map?hl=en-US&gl=US&ceid=US%3Aen https://mpidr.shinyapps.io/stmortality https://www.censtatd.gov.hk/en/EIndexbySubject.html?pcode=B1010002&scode=460 I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsPEMPercent excess mortalityPCEMPercent COVID-excess mortalityZCZero-COVIDLWCLiving-with COVIDWHOWorld Health Organization